Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Tebentafusp and Liver Radiotherapy for Patients with Metastatic Uveal Melanoma HLA A*02:01 Positive

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study examines the effectiveness of adding hepatic radiotherapy (radiation therapy directed at the liver) to the standard treatment with tebentafusp for patients with metastatic uveal melanoma that is HLA A*02:01 positive. Metastatic uveal melanoma is a rare form of eye cancer that has spread to other parts of the body, particularly the liver. The HLA A*02:01 refers to a specific genetic marker present in these patients that makes them eligible for this treatment approach.

The purpose of this study is to investigate whether adding liver-directed radiation therapy to standard treatment can prolong the time before the cancer progresses. Patients will receive the established treatment with tebentafusp (a medication that helps the immune system recognize and attack cancer cells) along with radiation therapy specifically targeting the liver metastases (cancer that has spread to the liver).

Throughout the study, patients will undergo regular assessments to monitor how their cancer responds to treatment, how long the treatment remains effective, and what side effects may occur. The study will also collect blood samples to analyze circulating tumor DNA and immune markers to better understand how the treatment affects the cancer at a molecular level.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Screening and Eligibility Confirmation

    You will undergo testing to confirm your HLA-A*02:01 positive metastatic uveal melanoma (a type of eye cancer that has spread) with liver metastases.

    The medical team will verify that you meet all requirements, including having at least one measurable liver lesion no larger than 8 cm, and adequate bone marrow, kidney, and liver function.

    You must be 18 years or older with an ECOG performance status of 0 or 1 (able to perform most daily activities).

  2. Step 2

    Treatment with Tebentafusp and Liver-Directed Therapy

    You will receive tebentafusp, which is the standard treatment for this type of cancer.

    In addition to the standard treatment, you will receive hepatic radiotherapy (radiation therapy directed at the liver).

    The purpose of adding liver-directed therapy to the standard treatment is to potentially prolong the time before the disease progresses.

  3. Step 3

    Regular Monitoring and Assessments

    Throughout the trial, you will have regular medical assessments to monitor your response to treatment.

    These assessments will include imaging scans to measure tumor size and blood tests to check your overall health status.

    The first tumor assessment will evaluate whether the treatment is controlling your disease.

  4. Step 4

    Continuation of Treatment

    You will continue receiving the treatment until your disease progresses, you experience unacceptable side effects, or you decide to withdraw from the study.

    During this time, ongoing assessments will track how your cancer responds to treatment.

  5. Step 5

    Follow-up Period

    After completing treatment, you will enter a follow-up period where your health will continue to be monitored.

    The medical team will track your progression-free survival (time from treatment start until the disease progresses) with special interest in the 6-month mark.

    Other measurements include overall survival, response to treatment, and time until you might need another type of treatment.

  6. Step 6

    Additional Research

    Blood samples will be collected to analyze your circulating immune profile and inflammatory markers.

    The study will also analyze ctDNA (circulating tumor DNA, which is genetic material from tumor cells found in your bloodstream) to correlate with your outcomes.

Who can join the trial?

13 criteria

  • You must have metastatic uveal melanoma (a type of eye cancer that has spread to other parts of the body) that is HLA-A*02:01 positive (a specific genetic marker)
  • You must have liver metastases (cancer that has spread to the liver), with at least one measurable tumor according to specific criteria
  • Your largest liver tumor must be 8 cm or smaller
  • You must be 18 years or older
  • You can be female or male
  • You must have good overall physical function (ECOG score of 0 or 1)
  • You must have adequate bone marrow function (healthy blood cell production)
  • You must have adequate kidney function (based on specific blood test values)
  • You must have adequate liver function (based on specific blood test values)
  • You must be willing and able to follow the study protocol
  • You must provide written informed consent
  • If you are a woman who can become pregnant, you must have a negative pregnancy test within 24 hours before starting the study
  • If you are a woman who can become pregnant or a man with a female partner who can become pregnant, you must use effective birth control during the study and for at least 1 week after the last treatment

Who cannot join the trial?

10 criteria

  • Previous treatment with immunotherapies targeting the MAGE A3, MAGE A4, MAGE A10, NYESO-1, or gp100 proteins (these are specific types of proteins targeted in certain cancer treatments)
  • Prior treatment with certain liver-directed therapies, including hepatic artery infusion (a way to deliver medicine directly to the liver) or radioembolization (a procedure that delivers radiation directly to liver tumors)
  • Active autoimmune disease requiring systemic treatment in the past 2 years (conditions where your immune system attacks your own body's tissues)
  • History of severe immune-related side effects from previous immunotherapy treatments
  • Uncontrolled brain metastases (cancer that has spread to the brain and is not under control)
  • Significant heart disease including heart failure, heart attack within 6 months, or uncontrolled high blood pressure
  • Serious infections requiring treatment
  • Pregnant or breastfeeding women
  • Known HIV, hepatitis B, or hepatitis C infection (specific viral infections)
  • Unable to understand or comply with study procedures
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Tebentafusp

    is a medication that helps the immune system recognize and attack cancer cells. It is specifically designed for patients with uveal melanoma (a type of eye cancer) that has spread to other parts of the body. Tebentafusp works by connecting T cells (a type of immune cell) to cancer cells, which helps the immune system find and destroy the cancer.

  • Hepatic radiotherapy

    is a treatment that uses radiation to target cancer in the liver. This approach directs radiation specifically to liver tumors while trying to minimize damage to healthy liver tissue. For patients with uveal melanoma that has spread to the liver, this targeted radiation therapy aims to control or reduce the liver tumors.

What is already known about the treatment

Tebentafusp – Tebentafusp is an intravenous medication administered via infusion that represents a significant advancement in the treatment of metastatic uveal melanoma, particularly in patients who are HLA A*02:01 positive. It functions as a bispecific fusion protein that connects T cells to melanoma cells, enabling the immune system to recognize and attack cancer cells. Tebentafusp works at the molecular level by binding to both the T-cell receptor and a protein called gp100 found on melanoma cells, creating a bridge that activates T cells to destroy the cancer. As the first approved immunotherapy specifically for uveal melanoma, this medication belongs to the class of bispecific T-cell engagers and has shown the ability to improve survival outcomes in patients with this rare and difficult-to-treat form of eye cancer.

Investigated diseases

Metastatic Uveal Melanoma – A condition that occurs when uveal melanoma, a rare cancer that originates in the eye's uveal tract (iris, ciliary body, and choroid), spreads beyond the eye to other parts of the body, most commonly the liver. The disease typically begins as a primary tumor in the eye, which can grow and eventually shed cancer cells that travel through the bloodstream. These cells can then establish new tumors in distant organs, marking the metastatic stage of the disease. Metastatic uveal melanoma progresses when these secondary tumors grow and multiply in the affected organs. The disease often develops silently, with metastases sometimes appearing years after treatment of the primary eye tumor.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-519760-40-00Protocol codeTEBE-RTEstimated enrolment20 patientsSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).